Originally developed for the management of type 2 diabetes, the glucagon-like peptide-1 (GLP-1) receptor agonist (RA), semaglutide, and GLP-1/glucose-dependent insulinotropic polypeptide dual RA, tirzepatide, have emerged as the most effective pharmacologic interventions for obesity treatment. Here, GLP1R is linked to obesity disorder.